Bio-Rad Laboratories, Inc. (BIO) EV/Assets Ratio: 0.89x
Is Bio-Rad Laboratories, Inc.’s EV/Assets ratio high or low?
Bio-Rad Laboratories, Inc.'s EV/Assets ratio of 0.89x is 10% below its 5-year average of 0.99x, near the low end of its 5-year range (0.67x–1.61x).
As of Wednesday, June 17, 2026. 1.47% above its 12-month average of 0.88x.
BIO EV/Assets Ratio Chart
BIO Average EV/Assets Ratio Chart
BIO Current vs Average EV/Assets Ratio Chart
BIO EV/Assets Ratio Metrics
EV/ASSETS RATIO
0.89x
EV/ASSETS RATIO AVG TTM
0.88x
EV/ASSETS RATIO AVG 3Y
0.89x
EV/ASSETS RATIO AVG 5Y
0.97x
EV/ASSETS RATIO AVG 10Y
1.23x
EV/ASSETS RATIO AVG 15Y
1.18x
EV/ASSETS RATIO AVG 20Y
1.20x
CURRENT VS TTM AVG
+1.47%
CURRENT VS 3Y AVG
+0.04%
CURRENT VS 5Y AVG
-8.19%
CURRENT VS 10Y AVG
-27.93%
CURRENT VS 15Y AVG
-24.29%
CURRENT VS 20Y AVG
-25.77%
BIO Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.84B | 0.89x | 0.88x | 0.89x | 0.97x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.02B | 3.57x | 5.78x | 7.31x | 5.77x |
| Tempus AI, Inc. (TEM)vs › | $8.82B | 4.61x | 6.22x | 7.85x | 7.85x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 1.54x | 1.51x | 1.59x | 1.95x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.56x | 0.52x | 0.58x | 0.69x |
| Baxter International Inc. (BAX)vs › | $10.57B | 0.92x | 0.91x | 1.05x | 1.32x |
| Revvity, Inc. (RVTY)vs › | $11.29B | 1.15x | 1.11x | 1.18x | 1.38x |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 1.89x | 1.75x | 2.55x | 3.74x |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 1.24x | 1.36x | 1.62x | 1.75x |
| Medpace Holdings, Inc. (MEDP)vs › | $13.18B | 6.03x | 8.01x | 6.58x | 5.71x |
Bio-Rad Laboratories, Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The EV/Assets ratio for BIO stock is 0.89x.
- Is Bio-Rad Laboratories, Inc.'s EV/Assets ratio high or low?
- Bio-Rad Laboratories, Inc.'s EV/Assets ratio of 0.89x is 10% below its 5-year average of 0.99x, near the low end of its 5-year range (0.67x–1.61x).
- What is the TTM average EV/Assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average EV/Assets ratio for BIO stock is 0.88x.
- What is the 3Y average EV/Assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average EV/Assets ratio for BIO stock is 0.89x.
- What is the 5Y average EV/Assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average EV/Assets ratio for BIO stock is 0.97x.
- What is the 10Y average EV/Assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average EV/Assets ratio for BIO stock is 1.23x.
- What is the 15Y average EV/Assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average EV/Assets ratio for BIO stock is 1.18x.
- What is the 20Y average EV/Assets ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average EV/Assets ratio for BIO stock is 1.20x.
Bio-Rad Laboratories, Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-16 | 0.89x |
| 2026-06-15 | 0.89x |
| 2026-06-12 | 0.88x |
| 2026-06-11 | 0.89x |
| 2026-06-10 | 0.89x |
| 2026-06-09 | 0.91x |
| 2026-06-08 | 0.89x |
| 2026-06-05 | 0.90x |
| 2026-06-04 | 0.94x |
| 2026-06-03 | 0.93x |
| 2026-06-02 | 0.93x |
| 2026-06-01 | 0.93x |
| 2026-05-29 | 0.95x |
| 2026-05-28 | 0.97x |
| 2026-05-27 | 0.93x |
| 2026-05-26 | 0.91x |
| 2026-05-22 | 0.88x |
| 2026-05-21 | 0.88x |
| 2026-05-20 | 0.88x |
| 2026-05-19 | 0.86x |
| 2026-05-18 | 0.86x |
| 2026-05-15 | 0.77x |
| 2026-05-14 | 0.77x |
| 2026-05-13 | 0.76x |
| 2026-05-12 | 0.75x |
| 2026-05-11 | 0.76x |
| 2026-05-08 | 0.79x |
| 2026-05-07 | 0.80x |
| 2026-05-06 | 0.80x |
| 2026-05-05 | 0.80x |
| 2026-05-04 | 0.80x |
| 2026-05-01 | 0.80x |
| 2026-04-30 | 0.86x |
| 2026-04-29 | 0.80x |
| 2026-04-28 | 0.81x |
| 2026-04-27 | 0.83x |
| 2026-04-24 | 0.83x |
| 2026-04-23 | 0.81x |
| 2026-04-22 | 0.86x |
| 2026-04-21 | 0.88x |
| 2026-04-20 | 0.87x |
| 2026-04-17 | 0.86x |
| 2026-04-16 | 0.84x |
| 2026-04-15 | 0.85x |
| 2026-04-14 | 0.84x |
| 2026-04-13 | 0.83x |
| 2026-04-10 | 0.81x |
| 2026-04-09 | 0.80x |
| 2026-04-08 | 0.81x |
| 2026-04-07 | 0.80x |
| 2026-04-06 | 0.81x |
| 2026-04-02 | 0.81x |
| 2026-04-01 | 0.81x |
| 2026-03-31 | 0.81x |
| 2026-03-30 | 0.78x |
| 2026-03-27 | 0.77x |
| 2026-03-26 | 0.80x |
| 2026-03-25 | 0.79x |
| 2026-03-24 | 0.79x |
| 2026-03-23 | 0.77x |
| 2026-03-20 | 0.77x |
| 2026-03-19 | 0.77x |
| 2026-03-18 | 0.78x |
| 2026-03-17 | 0.78x |
| 2026-03-16 | 0.76x |
| 2026-03-13 | 0.77x |
| 2026-03-12 | 0.76x |
| 2026-03-11 | 0.78x |
| 2026-03-10 | 0.78x |
| 2026-03-09 | 0.79x |
| 2026-03-06 | 0.78x |
| 2026-03-05 | 0.81x |
| 2026-03-04 | 0.82x |
| 2026-03-03 | 0.81x |
| 2026-03-02 | 0.81x |
| 2026-02-27 | 0.81x |
| 2026-02-26 | 0.80x |
| 2026-02-25 | 0.78x |
| 2026-02-24 | 0.78x |
| 2026-02-23 | 0.78x |
| 2026-02-20 | 0.79x |
| 2026-02-19 | 0.79x |
| 2026-02-18 | 0.79x |
| 2026-02-17 | 0.77x |
| 2026-02-13 | 0.75x |
| 2026-02-12 | 0.84x |
| 2026-02-11 | 0.92x |
| 2026-02-10 | 0.94x |
| 2026-02-09 | 0.92x |
| 2026-02-06 | 0.94x |
| 2026-02-05 | 0.93x |
| 2026-02-04 | 0.95x |
| 2026-02-03 | 0.93x |
| 2026-02-02 | 0.93x |
| 2026-01-30 | 0.92x |
| 2026-01-29 | 0.92x |
| 2026-01-28 | 0.94x |
| 2026-01-27 | 0.93x |
| 2026-01-26 | 0.93x |
| 2026-01-23 | 0.93x |
| 2026-01-22 | 0.95x |
| 2026-01-21 | 0.97x |
| 2026-01-20 | 0.97x |
| 2026-01-16 | 0.97x |
| 2026-01-15 | 1.00x |
| 2026-01-14 | 0.99x |
| 2026-01-13 | 1.00x |
| 2026-01-12 | 1.00x |
| 2026-01-09 | 1.00x |
| 2026-01-08 | 0.99x |
| 2026-01-07 | 1.00x |
| 2026-01-06 | 1.01x |
| 2026-01-05 | 1.00x |
| 2026-01-02 | 0.95x |
| 2025-12-31 | 0.94x |
| 2025-12-30 | 0.95x |
| 2025-12-29 | 0.95x |
| 2025-12-26 | 0.95x |
| 2025-12-24 | 0.94x |
| 2025-12-23 | 0.94x |
| 2025-12-22 | 0.95x |
| 2025-12-19 | 0.94x |
| 2025-12-18 | 0.94x |
| 2025-12-17 | 0.94x |
| 2025-12-16 | 0.94x |
| 2025-12-15 | 0.96x |
| 2025-12-12 | 0.96x |
| 2025-12-11 | 0.97x |
| 2025-12-10 | 0.98x |
| 2025-12-09 | 0.96x |
| 2025-12-08 | 0.96x |
| 2025-12-05 | 0.98x |
| 2025-12-04 | 0.99x |
| 2025-12-03 | 0.99x |
| 2025-12-02 | 0.99x |
| 2025-12-01 | 1.00x |
| 2025-11-28 | 1.00x |
| 2025-11-26 | 1.01x |
| 2025-11-25 | 1.03x |
| 2025-11-24 | 1.00x |
| 2025-11-21 | 0.98x |
| 2025-11-20 | 0.95x |
| 2025-11-19 | 0.95x |
| 2025-11-18 | 0.96x |
| 2025-11-17 | 0.95x |
| 2025-11-14 | 0.97x |
| 2025-11-13 | 0.98x |
| 2025-11-12 | 1.01x |
| 2025-11-11 | 0.97x |
| 2025-11-10 | 0.96x |
| 2025-11-07 | 0.95x |
| 2025-11-06 | 0.95x |
| 2025-11-05 | 0.96x |
| 2025-11-04 | 0.97x |
| 2025-11-03 | 0.97x |
| 2025-10-31 | 0.99x |
| 2025-10-30 | 0.95x |
| 2025-10-29 | 0.99x |
| 2025-10-28 | 0.98x |
| 2025-10-27 | 1.00x |
| 2025-10-24 | 1.01x |
| 2025-10-23 | 1.00x |
| 2025-10-22 | 0.99x |
| 2025-10-21 | 0.98x |
| 2025-10-20 | 0.96x |
| 2025-10-17 | 0.93x |
| 2025-10-16 | 0.93x |
| 2025-10-15 | 0.92x |
| 2025-10-14 | 0.91x |
| 2025-10-13 | 0.91x |
| 2025-10-10 | 0.90x |
| 2025-10-09 | 0.90x |
| 2025-10-08 | 0.91x |
| 2025-10-07 | 0.89x |
| 2025-10-06 | 0.93x |
| 2025-10-03 | 0.92x |
| 2025-10-02 | 0.89x |
| 2025-10-01 | 0.90x |
| 2025-09-30 | 0.85x |
| 2025-09-29 | 0.82x |
| 2025-09-26 | 0.82x |
| 2025-09-25 | 0.82x |
| 2025-09-24 | 0.84x |
| 2025-09-23 | 0.85x |
| 2025-09-22 | 0.86x |
| 2025-09-19 | 0.86x |
| 2025-09-18 | 0.87x |
| 2025-09-17 | 0.85x |
| 2025-09-16 | 0.85x |
| 2025-09-15 | 0.85x |
| 2025-09-12 | 0.85x |
| 2025-09-11 | 0.86x |
| 2025-09-10 | 0.84x |
| 2025-09-09 | 0.86x |
| 2025-09-08 | 0.88x |
| 2025-09-05 | 0.89x |
| 2025-09-04 | 0.87x |
| 2025-09-03 | 0.87x |
| 2025-09-02 | 0.88x |
| 2025-08-29 | 0.90x |
| 2025-08-28 | 0.88x |
| 2025-08-27 | 0.88x |
| 2025-08-26 | 0.89x |
| 2025-08-25 | 0.89x |
| 2025-08-22 | 0.91x |
| 2025-08-21 | 0.86x |
| 2025-08-20 | 0.87x |
| 2025-08-19 | 0.87x |
| 2025-08-18 | 0.86x |
| 2025-08-15 | 0.86x |
| 2025-08-14 | 0.87x |
| 2025-08-13 | 0.87x |
| 2025-08-12 | 0.83x |
| 2025-08-11 | 0.81x |
| 2025-08-08 | 0.81x |
| 2025-08-07 | 0.81x |
| 2025-08-06 | 0.81x |
| 2025-08-05 | 0.83x |
| 2025-08-04 | 0.84x |
| 2025-08-01 | 0.86x |
| 2025-07-31 | 0.75x |
| 2025-07-30 | 0.82x |
| 2025-07-29 | 0.83x |
| 2025-07-28 | 0.83x |
| 2025-07-25 | 0.86x |
| 2025-07-24 | 0.86x |
| 2025-07-23 | 0.84x |
| 2025-07-22 | 0.81x |
| 2025-07-21 | 0.81x |
| 2025-07-18 | 0.81x |
| 2025-07-17 | 0.82x |
| 2025-07-16 | 0.81x |
| 2025-07-15 | 0.81x |
| 2025-07-14 | 0.82x |
| 2025-07-11 | 0.84x |
| 2025-07-10 | 0.85x |
| 2025-07-09 | 0.83x |
| 2025-07-08 | 0.82x |
| 2025-07-07 | 0.81x |
| 2025-07-03 | 0.83x |
| 2025-07-02 | 0.82x |
| 2025-07-01 | 0.82x |
| 2025-06-30 | 0.80x |
| 2025-06-27 | 0.80x |
| 2025-06-26 | 0.80x |
| 2025-06-25 | 0.80x |
| 2025-06-24 | 0.79x |
| 2025-06-23 | 0.78x |
| 2025-06-20 | 0.78x |
| 2025-06-18 | 0.77x |
| 2025-06-17 | 0.77x |
| 2025-06-16 | 0.77x |
| 2025-06-13 | 0.75x |
| 2025-06-12 | 0.77x |
| 2025-06-11 | 0.76x |
| 2025-06-10 | 0.77x |
| 2025-06-09 | 0.75x |
| 2025-06-06 | 0.73x |
| 2025-06-05 | 0.73x |
| 2025-06-04 | 0.74x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz